{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/36708"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/36708","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"Characterization of IGCR-1: a novel molecule with potential roles in lung carcinogenesis","abstract":"Non-small cell lung cancer (NSCLC) patients respond poorly to generic chemotherapeutics. Despite recent advancements in the treatment of NSCLC, the overall five-year survival rate of NSCLC remains low at 14.6%. We have identified Immunoglobulin-containing and Cysteine-rich Receptor (IGCR-1) as a putative cell surface protein, which is expressed in lung epithelial cells. The main objectives of this study were to evaluate expression of IGCR-1 in normal lung epithelium and lung carcinoma. Our analysis of publicly available ATCG data via bioGPS revealed that IGCR-1 is highly expressed in human lung. Moreover, our immunohistochemical studies further confirmed that IGCR-1 is expressed in bronchial epithelial cells. Additionally, IGCR-1 is expressed in endothelial cells of blood vessels and localized on the cell surface of human embryonic kidney cells. Its cell surface localization suggests that IGCR-1 could be a cellular adhesion molecule (CAM) with roles in the tumor microenvironment. Of note, the analysis of a panel of human lung carcinoma cell lines via western blot analysis demonstrated that IGCR-1 is expressed at variable levels in these cell lines. Given the heterogeneity of NSCLSs and the corresponding differential expression of IGCR-1 in different lung cancer cell lines, IGCR-1 may play an important role in NSCLCs.","abstract_html":"Non-small cell lung cancer (NSCLC) patients respond poorly to generic chemotherapeutics. Despite recent advancements in the treatment of NSCLC, the overall five-year survival rate of NSCLC remains low at 14.6%. We have identified Immunoglobulin-containing and Cysteine-rich Receptor (IGCR-1) as a putative cell surface protein, which is expressed in lung epithelial cells. The main objectives of this study were to evaluate expression of IGCR-1 in normal lung epithelium and lung carcinoma. Our analysis of publicly available ATCG data via bioGPS revealed that IGCR-1 is highly expressed in human lung. Moreover, our immunohistochemical studies further confirmed that IGCR-1 is expressed in bronchial epithelial cells. Additionally, IGCR-1 is expressed in endothelial cells of blood vessels and localized on the cell surface of human embryonic kidney cells. Its cell surface localization suggests that IGCR-1 could be a cellular adhesion molecule (CAM) with roles in the tumor microenvironment. Of note, the analysis of a panel of human lung carcinoma cell lines via western blot analysis demonstrated that IGCR-1 is expressed at variable levels in these cell lines. Given the heterogeneity of NSCLSs and the corresponding differential expression of IGCR-1 in different lung cancer cell lines, IGCR-1 may play an important role in NSCLCs.","abstract_has_math":false,"creators":["Lam, Christa Mercy"],"institution":"Boston University","degree_name":"Master of Science","degree_level":"masters","degree_discipline":"Medical Sciences","degree_department":null,"school":null,"contributors":[],"advisors":["Rahimi, Nader"],"committee_chairs":[],"committee_members":[],"year":2019,"date_issued":"2019","date_published":"2019","updated_at":"2026-11-19T02:41:09Z","subjects":["Biochemistry"],"languages":["en_US"],"rights":["Attribution-NonCommercial-NoDerivatives 4.0 International"],"rights_urls":["http://creativecommons.org/licenses/by-nc-nd/4.0/"],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2144/36708","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/36708","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F36708","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Rahimi, Nader"]},{"key":"dc:creator","label":"Author","values":["Lam, Christa Mercy"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2019-07-30T14:34:45Z"]},{"key":"dc:date.embargo","label":"Dc Date Embargo","values":["2020-06-17T00:00:00Z"]},{"key":"dc:date.issued","label":"Date","values":["2019"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2019-06-17T19:19:43Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Medical Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["masters"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Biochemistry"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]},{"key":"dc:rights","label":"Dc Rights","values":["Attribution-NonCommercial-NoDerivatives 4.0 International"]},{"key":"dc:rights.uri","label":"Rights URI","values":["http://creativecommons.org/licenses/by-nc-nd/4.0/"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/36708"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Non-small cell lung cancer (NSCLC) patients respond poorly to generic chemotherapeutics. Despite recent advancements in the treatment of NSCLC, the overall five-year survival rate of NSCLC remains low at 14.6%. We have identified Immunoglobulin-containing and Cysteine-rich Receptor (IGCR-1) as a putative cell surface protein, which is expressed in lung epithelial cells. The main objectives of this study were to evaluate expression of IGCR-1 in normal lung epithelium and lung carcinoma. Our analysis of publicly available ATCG data via bioGPS revealed that IGCR-1 is highly expressed in human lung. Moreover, our immunohistochemical studies further confirmed that IGCR-1 is expressed in bronchial epithelial cells. Additionally, IGCR-1 is expressed in endothelial cells of blood vessels and localized on the cell surface of human embryonic kidney cells. Its cell surface localization suggests that IGCR-1 could be a cellular adhesion molecule (CAM) with roles in the tumor microenvironment. Of note, the analysis of a panel of human lung carcinoma cell lines via western blot analysis demonstrated that IGCR-1 is expressed at variable levels in these cell lines. Given the heterogeneity of NSCLSs and the corresponding differential expression of IGCR-1 in different lung cancer cell lines, IGCR-1 may play an important role in NSCLCs."]},{"key":"dc:title","label":"Title","values":["Characterization of IGCR-1: a novel molecule with potential roles in lung carcinogenesis"]}]}],"canonical_facts":{"dc:contributor.advisor":["Rahimi, Nader"],"dc:creator":["Lam, Christa Mercy"],"dc:date.accessioned":["2019-07-30T14:34:45Z"],"dc:date.embargo":["2020-06-17T00:00:00Z"],"dc:date.issued":["2019"],"dc:date.updated":["2019-06-17T19:19:43Z"],"dc:description.abstract":["Non-small cell lung cancer (NSCLC) patients respond poorly to generic chemotherapeutics. Despite recent advancements in the treatment of NSCLC, the overall five-year survival rate of NSCLC remains low at 14.6%. We have identified Immunoglobulin-containing and Cysteine-rich Receptor (IGCR-1) as a putative cell surface protein, which is expressed in lung epithelial cells. The main objectives of this study were to evaluate expression of IGCR-1 in normal lung epithelium and lung carcinoma. Our analysis of publicly available ATCG data via bioGPS revealed that IGCR-1 is highly expressed in human lung. Moreover, our immunohistochemical studies further confirmed that IGCR-1 is expressed in bronchial epithelial cells. Additionally, IGCR-1 is expressed in endothelial cells of blood vessels and localized on the cell surface of human embryonic kidney cells. Its cell surface localization suggests that IGCR-1 could be a cellular adhesion molecule (CAM) with roles in the tumor microenvironment. Of note, the analysis of a panel of human lung carcinoma cell lines via western blot analysis demonstrated that IGCR-1 is expressed at variable levels in these cell lines. Given the heterogeneity of NSCLSs and the corresponding differential expression of IGCR-1 in different lung cancer cell lines, IGCR-1 may play an important role in NSCLCs."],"dc:identifier.uri":["https://hdl.handle.net/2144/36708"],"dc:language.iso":["en_US"],"dc:rights":["Attribution-NonCommercial-NoDerivatives 4.0 International"],"dc:rights.uri":["http://creativecommons.org/licenses/by-nc-nd/4.0/"],"dc:subject":["Biochemistry"],"dc:title":["Characterization of IGCR-1: a novel molecule with potential roles in lung carcinogenesis"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Medical Sciences"],"thesis:degree_level":["masters"],"thesis:degree_name":["Master of Science"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-19T02:41:09Z"}